These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

143 related articles for article (PubMed ID: 8376690)

  • 21. Trial design and reporting standards for intra-arterial cerebral thrombolysis for acute ischemic stroke.
    Higashida RT; Furlan AJ; Roberts H; Tomsick T; Connors B; Barr J; Dillon W; Warach S; Broderick J; Tilley B; Sacks D; ;
    Stroke; 2003 Aug; 34(8):e109-37. PubMed ID: 12869717
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Reliability of ventricular remodeling as a surrogate for use in conjunction with clinical outcomes in heart failure.
    Konstam MA
    Am J Cardiol; 2005 Sep; 96(6):867-71. PubMed ID: 16169379
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Challenges of subgroup analyses in multinational clinical trials: experiences from the MERIT-HF trial.
    Wedel H; Demets D; Deedwania P; Fagerberg B; Goldstein S; Gottlieb S; Hjalmarson A; Kjekshus J; Waagstein F; Wikstrand J;
    Am Heart J; 2001 Sep; 142(3):502-11. PubMed ID: 11526365
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Objective response by mRECIST as a predictor and potential surrogate end-point of overall survival in advanced HCC.
    Lencioni R; Montal R; Torres F; Park JW; Decaens T; Raoul JL; Kudo M; Chang C; Ríos J; Boige V; Assenat E; Kang YK; Lim HY; Walters I; Llovet JM
    J Hepatol; 2017 Jun; 66(6):1166-1172. PubMed ID: 28131794
    [TBL] [Abstract][Full Text] [Related]  

  • 25. GFR decline as an alternative end point to kidney failure in clinical trials: a meta-analysis of treatment effects from 37 randomized trials.
    Inker LA; Lambers Heerspink HJ; Mondal H; Schmid CH; Tighiouart H; Noubary F; Coresh J; Greene T; Levey AS
    Am J Kidney Dis; 2014 Dec; 64(6):848-59. PubMed ID: 25441438
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Chemoprevention trials and surrogate end point biomarkers in the cervix.
    Mitchell MF; Hittelman WK; Lotan R; Nishioka K; Tortolero-Luna G; Richards-Kortum R; Wharton JT; Hong WK
    Cancer; 1995 Nov; 76(10 Suppl):1956-77. PubMed ID: 8634987
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Effects of controlled-release metoprolol on total mortality, hospitalizations, and well-being in patients with heart failure: the Metoprolol CR/XL Randomized Intervention Trial in congestive heart failure (MERIT-HF). MERIT-HF Study Group.
    Hjalmarson A; Goldstein S; Fagerberg B; Wedel H; Waagstein F; Kjekshus J; Wikstrand J; El Allaf D; Vítovec J; Aldershvile J; Halinen M; Dietz R; Neuhaus KL; Jánosi A; Thorgeirsson G; Dunselman PH; Gullestad L; Kuch J; Herlitz J; Rickenbacher P; Ball S; Gottlieb S; Deedwania P
    JAMA; 2000 Mar; 283(10):1295-302. PubMed ID: 10714728
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Glomerular filtration rate decline as a surrogate end point in kidney disease progression trials.
    Badve SV; Palmer SC; Hawley CM; Pascoe EM; Strippoli GF; Johnson DW
    Nephrol Dial Transplant; 2016 Sep; 31(9):1425-36. PubMed ID: 26163881
    [TBL] [Abstract][Full Text] [Related]  

  • 29. FDA's proposed regulations to expand access to investigational drugs for treatment use: the status quo in the guise of reform.
    Rossen BR
    Food Drug Law J; 2009; 64(1):183-223. PubMed ID: 19998746
    [TBL] [Abstract][Full Text] [Related]  

  • 30. End points in cancer clinical trials and the drug approval process.
    Schilsky RL
    Clin Cancer Res; 2002 Apr; 8(4):935-8. PubMed ID: 11948095
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Developing biomarker-specific end points in lung cancer clinical trials.
    Neal JW; Gainor JF; Shaw AT
    Nat Rev Clin Oncol; 2015 Mar; 12(3):135-46. PubMed ID: 25533947
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Perceived benefit after participating in positive or negative/neutral heart failure trials: the patients' perspective.
    Yuval R; Uziel K; Gordon N; Merdler A; Khader N; Karkabi B; Flugelman MY; Halon DA; Lewis BS
    Eur J Heart Fail; 2001 Mar; 3(2):217-23. PubMed ID: 11246060
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Newer drugs for heart failure: hype or hope?
    Ghali JK
    Expert Opin Investig Drugs; 2017 Jan; 26(1):5-7. PubMed ID: 27828719
    [No Abstract]   [Full Text] [Related]  

  • 34. End points and United States Food and Drug Administration approval of oncology drugs.
    Johnson JR; Williams G; Pazdur R
    J Clin Oncol; 2003 Apr; 21(7):1404-11. PubMed ID: 12663734
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Cardiovascular biomarkers and surrogate end points: key initiatives and clinical trial challenges.
    Heinonen TM; Aamer M; Marshall C; Black DM; Tardif JC
    Expert Rev Cardiovasc Ther; 2012 Aug; 10(8):989-94. PubMed ID: 23030288
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Skin as a surrogate tissue for pharmacodynamic end points: is it deep enough?
    Baselga J
    Clin Cancer Res; 2003 Jul; 9(7):2389-90. PubMed ID: 12855608
    [No Abstract]   [Full Text] [Related]  

  • 37. Hemodynamics as surrogate end points for survival in advanced heart failure: an analysis from FIRST.
    Shah MR; Stinnett SS; McNulty SE; Gheorghiade M; Zannad F; Uretsky B; Adams KF; Califf RM; O'connor CM
    Am Heart J; 2001 Jun; 141(6):908-14. PubMed ID: 11376303
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Rationale, application and clinical qualification for NT-proBNP as a surrogate end point in pivotal clinical trials in patients with AL amyloidosis.
    Merlini G; Lousada I; Ando Y; Dispenzieri A; Gertz MA; Grogan M; Maurer MS; Sanchorawala V; Wechalekar A; Palladini G; Comenzo RL
    Leukemia; 2016 Oct; 30(10):1979-1986. PubMed ID: 27416985
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Time to Review the Role of Surrogate End Points in Health Policy: State of the Art and the Way Forward.
    Ciani O; Buyse M; Drummond M; Rasi G; Saad ED; Taylor RS
    Value Health; 2017 Mar; 20(3):487-495. PubMed ID: 28292495
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Research priorities in biomarkers and surrogate end-points.
    Aronson JK
    Br J Clin Pharmacol; 2012 Jun; 73(6):900-7. PubMed ID: 22360291
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.